Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
J Biol Chem. 2011 Apr 8;286(14):12785-95. doi: 10.1074/jbc.M110.203091. Epub 2011 Feb 17.
Agonist stimulation of the β2-adrenergic receptors (β2ARs) leads to their ubiquitination and lysosomal degradation. Inhibition of lysosomal proteases results in the stabilization and retention of internalized full-length β2ARs in the lysosomes, whereas inhibition of proteasomal proteases stabilizes newly synthesized β2ARs in nonlysosomal compartments. Additionally, a lysine-less β2AR (0K-β2AR) that is deficient in ubiquitination and degradation is not sorted to lysosomes unlike the WT β2AR, which is sorted to lysosomes. Thus, lysosomes are the primary sites for the degradation of agonist-activated, ubiquitinated β2ARs. To identify the specific site(s) of ubiquitination required for lysosomal sorting of the β2AR, four mutants, with lysines only in one intracellular domain, namely, loop 1, loop 2, loop 3, and carboxyl tail were generated. All of these receptor mutants coupled to G proteins, recruited β-arrestin2, and internalized just as the WT β2AR. However, only loop 3 and carboxyl tail β2ARs with lysines in the third intracellular loop or in the carboxyl tail were ubiquitinated and sorted for lysosomal degradation. As a complementary approach, we performed MS-based proteomic analyses to directly identify ubiquitination sites within the β2AR. We overexpressed and purified the β2AR from HEK-293 cells with or without prior agonist exposure and subjected trypsin-cleaved β2AR to LC-MS/MS analyses. We identified ubiquitinated lysines in the third intracellular loop (Lys-263 and Lys-270) and in the carboxyl tail (Lys-348, Lys-372, and Lys-375) of the β2AR. These findings introduce a new concept that two distinct domains in the β2AR are involved in ubiquitination and lysosomal degradation, contrary to the generalization that such regulatory mechanisms occur mainly at the carboxyl tails of GPCRs and other transmembrane receptors.
激动剂刺激β2-肾上腺素能受体(β2ARs)导致它们泛素化和溶酶体降解。溶酶体蛋白酶抑制剂导致内化的全长β2AR 在溶酶体中稳定和保留,而蛋白酶体蛋白酶抑制剂稳定新合成的β2AR 在非溶酶体区室中。此外,缺乏泛素化和降解的赖氨酸缺失β2AR(0K-β2AR)与 WT β2AR 不同,它不被分拣到溶酶体中,而 WT β2AR 被分拣到溶酶体中。因此,溶酶体是降解激动剂激活的、泛素化的β2AR 的主要场所。为了确定β2AR 溶酶体分拣所需的泛素化的特定位点,生成了四个突变体,它们只有一个细胞内域中的赖氨酸,即环 1、环 2、环 3 和羧基尾。所有这些受体突变体都与 G 蛋白偶联,招募β-arrestin2,并像 WT β2AR 一样内化。然而,只有环 3 和羧基尾β2AR 中的赖氨酸在第三细胞内环或羧基尾中被泛素化并分拣到溶酶体中进行降解。作为一种补充方法,我们进行了基于 MS 的蛋白质组学分析,以直接鉴定β2AR 内的泛素化位点。我们从 HEK-293 细胞中转基因表达和纯化了β2AR,无论是否事先暴露于激动剂,并用胰蛋白酶切割的β2AR 进行 LC-MS/MS 分析。我们鉴定了β2AR 第三细胞内环(Lys-263 和 Lys-270)和羧基尾(Lys-348、Lys-372 和 Lys-375)中的泛素化赖氨酸。这些发现引入了一个新概念,即β2AR 中的两个不同结构域参与泛素化和溶酶体降解,这与这种调节机制主要发生在 GPCR 和其他跨膜受体的羧基尾部的普遍观点相反。